Article page



Full Text:


Introduction. Hygienic rationing of the content of adverse substances in the air on the basis of an experimental study of their toxicity is aimed at the elaboration and creation of safe working conditions. Material and methods. The toxic properties of the salicylic acid derivative (Mesalazine) have been studied in the experiments on out-bred and linear mice, rats, Guinea pigs, and rabbits kept in standard vivarium conditions and quarantined. In the experiments, various modes (single, repeated, chronic) and ways of exposure (intragastric, inhalation, epicutaneous) were simulated. The average lethal dose (LD50) of Mesalazine and the threshold of a single acute exposure (Limas) were determined; irritant effect on the skin and mucous membranes, cumulative and allergenic activity were estimated. In subacute and chronic intake, the main target organs were determined based on the results of biochemical and hematological studies. Results. By the value of the average lethal doses Mesalazine has been established to have to be classified as a substance of the 3rd hazard class (moderately hazardous). There were no significant differences in the species and the gender susceptibility of the animals to Mesalazine: the coefficient of species differences was 2.84; the coefficient of the gender susceptibility was 1.2, which was less than 3 units. In terms of the degree of specific blood damage, Mesalazine belongs to class V (no effect of the selective influence of the drug on the imbalance of various hemoglobin forms). Mesalazine has a weak ability to cumulate, have no irritating effects on the eyes and skin. Skin-resorptive and sensitizing effects were not revealed. Limas under the conditions of dynamic inhalation exposure is set at 30.4 mg/m3. Conclusion. Maximum allowable concentration (MAC) of Mesalazine in the air of the working area as 0.5 mg/m3 is recommended (hazard class II). Compliance with this standard will ensure the health preservation and will eliminate the risk of developing occupational diseases.

Для цитирования:

For citation:


  • Refbacks are not listed

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 3.0 License.

ISSN: (Print)
ISSN: (Online)